The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

ABSTRACT - 592437 Disclosed herein is a dosage form comprising: at least one form of tapentadol at least one opioid antagonist and a second analgesic wherein the said opioid antagonist improves the efficacy and or reduces the side effects of tapentadol and wherein said opioid antagonist is selected from the group consisting of naloxone naltrexone nalmefene methylnaltrexone nalide nalmexone nalorphine naluphine haloperidol promethazine fluphenazine perphenazine levomepromazine thioridazine perazi...